IMM 1.59% 31.0¢ immutep limited

prima biomed to release interim cvac clinical

  1. 7,597 Posts.
    lightbulb Created with Sketch. 44
    The faithful are slow this morning...


    Prima BioMed Ltd (ASX: PRR, NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim results from its CVac™ clinical trial CAN-003 in October 2012.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.